Enfuvirtide injection site reactions: A clinical and histopathological appraisal

Australasian Journal of Dermatology

Volumn 52, Issue 1, 2011, Pages 19-26

  Wallace, Brian J ^a   Tan, King Bing ^d   Pett, Sarah L ^a,b   Cooper, David A ^a,b   Kossard, Steven ^c   Whitfeld, Margot J ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SKIN AND CANCER FOUNDATION AUSTRALIA   (Australia)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

CD34+; Dermal dendritic cell; Enfuvirtide; Factor XIIIa; HIV; Injection site reactions

Indexed keywords

BLOOD CLOTTING FACTOR 13A; CD34 ANTIGEN; CD68 ANTIGEN; COLLAGEN; ENFUVIRTIDE; INSULIN; MOMETASONE FUROATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROCOLLAGEN; PROTEIN S 100; RALTEGRAVIR; RECOMBINANT INTERLEUKIN 2; VIMENTIN;

ADULT; ARTICLE; CASE REPORT; CELL INFILTRATION; CONNECTIVE TISSUE; DENDRITIC CELL; DERMAL DENDRITIC CELLS; DERMIS; DRUG WITHDRAWAL; EPIDERMIS; HISTIOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; INJECTION SITE ATROPHY; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE TENDERNESS; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MORPHEA; MULTIPLE CYCLE TREATMENT; PUNCH BIOPSY; SCLERODERMA; SKIN BIOPSY; SKIN FIBROSIS; SUBCUTANEOUS TISSUE; TREATMENT DURATION; UMBILICUS;

BIOPSY; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN;

EID: 79952051338     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2010.00717.x     Document Type: Article

References (32)

1. Cooper DA, Lange JM. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. Lancet Infect. Dis. 2004; 4: 426-36.
2. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 2003; 348: 2186-95.
3. Lalezari JP, Patel IH, Zhang X et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1 infected patients. J. Clin. Virol. 2003; 28: 217-22.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available from URL: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Accessed 12 Jun 2010).
5. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. December 2004. Available from URL: http://www.ucdmc.ucdavis.edu/ clinicaltrials/documents/DAIDS-AE-GradingTable-FinalDec2004.pdf (Accessed 12 Jun 2010).
6. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 2008; 359: 355-65.
7. Arasteh K, Yeni P, Pozniak A et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir. Ther. 2009; 14: 859-64.
8. Boyd MA, Truman M, Hales G et al. A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). Antivir. Ther. 2008; 13: 449-53. (Pubitemid 352022554)
9. INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee, Abrams D, Levy Y, Losso MH et al. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 2009; 361: 1548-59.
10. Ball RA, Kinchelow T, ISR Substudy Group. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J. Am. Acad. Dermatol. 2003; 49: 826-31.
11. Maggi P, Ladisa N, Cinori E et al. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J. Antimicrob. Chemoth. 2004; 53: 678-81.
12. Morilla ME, Kocher J, Harmaty M. Localized amyloidosis at the site of enfuvirtide injection. Ann. Intern. Med. 2009; 151: 515-16.
13. Kamath NV, Ormsby A, Bergfeld WF et al. A light microscopic and immunohistochemical evaluation of scars. J. Cutan. Pathol. 2002; 29: 27-32.
14. Walters R, Pulitzer M, Kamino H. Elastic fiber pattern in scleroderma/morphea. J. Cutan. Pathol. 2009; 36: 952-57.
15. Winer LH. Elastic fibers in unusual dermatoses. Arch. Dermatol. 1955; 71: 338.
16. McKee PH, Calonje E, Granter SR. Idiopathic connective tissue disorders. In: McKee PH, Calonje E, Granter SR (eds). Pathology of the Skin with Clinical Correlations. London: Elsevier Mosby, 2005; 815.
17. Skobieranda K, Helm KF. Decreased expression of the human progenitor cell antigen (CD34) in morphea. Am. J. Dermatopathol. 1995; 17: 471-5.
18. Paye M, Nusgens BV, Lapière CM. Factor XIII of blood coagulation modulates collagen biosynthesis by fibroblasts in vitro. Haemostasis 1989; 19: 274-83. (Pubitemid 19224095)
19. Longacre TA, Smoller BR, Rouse RV. Atypical fibroxanthoma. Multiple immunohistologic profiles. Am. J. Surg. Pathol. 1993; 17: 1199-209.
20. Cerio R, Griffiths CE, Cooper KD et al. Characterisation of Factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br. J. Dermatol. 1989; 121: 421-31.
21. Gibran NS, Heimbach DM, Holbrook KA. Immunolocalization of FXIIIa+ dendritic cells in human burn wounds. J. Surg. Res. 1995; 59: 378-86.
22. Onodera M, Ueno M, Ito O et al. Factor XIIIa-positive dermal dendritic cells in keloids and hypertrophic and mature scars. Pathol. Int. 2007; 57: 337-42.
23. Gilmour TK, Wilkinson B, Breit SN et al. Analysis of dendritic cell populations using a revised histological staging of morphoea. Br. J. Dermatol. 2000; 143: 1183-92.
24. Rozario JA, Jasani B, Gaskell S et al. Analysis of dendritic cell populations in lichen sclerosis. Br. J. Dermatol. 2002; 147 (Suppl. 62): 75.
25. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615-27. (Pubitemid 39095778)
26. Dwyer DE, Workman C, Hales G et al. Alliance Study Group. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study. Antivir. Ther. 2006; 11: 409-19.
27. Haustein U-F, Haupt B. Drug-Induced Scleroderma and Sclerodermiform Conditions. Clin. Dermatol. 1998; 16: 353-66.
28. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 2005; 352: 48-62.
29. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8.
30. He Y, Xiao Y, Song H et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 2008; 283: 11126-34.
31. Jacobson JM, Thompson MA, Lalezari JP et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J. Infect. Dis. 2010; 201: 1481-7.
32. Falutz J, Potvin D, Mamputu JC et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J. Acquir. Immune Defic. Syndr. 2010; 53: 311-22.